ArticleImmuno-oncology technology2025
Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab.
Article in Immuno-oncology technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Uveal melanoma (UM) is a rare cancer, which often metastasizes to the liver, leading to a poor prognosis. In the randomized SCANDIUM II trial, patients with metastatic UM received a one-time treatment with isolated hepatic perfusion using high-dose melphalan in combination with systemic immune checkpoint inhibition with ipilimumab (3 mg/kg) and nivolumab (1 mg/kg). In this study, we assessed circulating tumor DNA (ctDNA) in prospectively collected blood samples from all patients in the SCANDIUM II trial to detect residual disease and recurrence as a strategy to evaluate treatment efficacy and predict prognosis. Patients and methods: We analyzed ctDNA in 128 plasma samples from 18 patients using digital PCR (Oncobit™ PM) targeting GNA11 Q209L ( Results: At baseline, ctDNA was detectable in 9 of 17 (53%) patients, with levels positively correlated with lactate dehydrogenase and tumor burden. Analysis of ctDNA dynamics revealed ctDNA increase before progression in a subset of patients (5 of 12 patients, 42%). After treatment initiation, six of seven (86%) patients showed ctDNA clearance or decrease. Patients with undetectable ctDNA 2-4 months after the start of treatment had significantly improved progression-free survival ( Conclusions: In patients with UM liver metastases treated with combined hepatic perfusion and immune checkpoint inhibition, ctDNA may serve as a predictive biomarker and warrants further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.